PDL BioPharma Financial Statements
PDL BioPharma Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
PDL BioPharma Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 294.3 | 258.9 | 414.8 |
| Gross Profit ($ mil.) | -- | -- | 328.5 |
| Operating Income ($ mil.) | 257.6 | (5.4) | (116.2) |
| Total Net Income ($ mil.) | 68.4 | (21.1) | (130.0) |
| Diluted EPS (Net Income) | 0.47 | (0.18) | (1.14) |
PDL BioPharma Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 71.4 | 125.9 | 62.6 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | 66.7 | 121.8 | 58.3 |
| Total Net Income ($ mil.) | 46.4 | 77.2 | 37.5 |
| Diluted EPS (Net Income) | 0.29 | 0.47 | 0.23 |
PDL BioPharma Stock Quote & Chart
11/09/09 12:59:10 EST •
NASDAQ •
8.15
•
 -0.0400
•
-0.4884 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
PDL BioPharma Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 4.46 | 7.55 | 7.01 |
| Price/Earnings Ratio | 6.59 | 93.46 | 25.51 |
| Price/Book Ratio | (3.19) | 3.48 | 6.74 |
| Price/Cash Flow Ratio | 8.25 | 41.49 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed PDL BioPharma Financial Ratios
PDL BioPharma Competitive Intelligence
| Medarex | Seattle Genetics | XOMA | |
|---|---|---|---|
| Annual Sales ($ mil.) | 52.3 | 35.2 | 68.0 |
| Employees | 488 | 261 | 335 |
| Market Cap ($ mil.) | 2,067.4 | 823.6 | 125.4 |
Competitive Landscape
